<DOC>
	<DOC>NCT00605722</DOC>
	<brief_summary>This single arm study evaluated the efficacy and safety of a combination of Tarceva and Avastin in patients with advanced or metastatic liver cancer. Patients were treated with Tarceva 150 mg po daily plus Avastin 5 mg/kg intravenous (iv) every 2 weeks. The anticipated time on study treatment was until disease progression, and the target sample size was &lt;100 individuals.</brief_summary>
	<brief_title>A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.</brief_title>
	<detailed_description />
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patients, ≥ 18 years of age; advanced or metastatic liver cancer; ≥ 1 measurable lesion, not previously treated with local therapy within 4 weeks of enrollment. prior or concomitant systemic anticancer treatment for advanced disease; patients at high risk of variceal bleeding; clinically significant cardiovascular disease; major surgery, open biopsy, or significant traumatic injury within 4 weeks of study start.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>